A practical reference on shelf life: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-24. Anything still debated is marked as such rather than presented as settled.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
=== Pharmacodynamics === SR-17018 acts as a biased partial agonist of the μ-opioid receptor (MOR), with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its affinities (Ki) for the human opioid receptors have been reported to be 11 nM for the MOR, 68 nM for the κ-opioid receptor (KOR), and >10,000 nM for the δ-opioid receptor (DOR). In terms of MOR activation, the drug had activational potencies and efficacies (EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy) of 97–193 nM (72–75%) for GTPγS binding, 76 nM (105%) for cAMPTooltip cyclic adenosine monophosphate accumulation, and >10,000 nM (10%) for β-arrestin2 recruitment. Both GTPγS binding and cAMP accumulation are measures of G protein signaling. The drug showed a calculated bias factor for GTPγS binding over β-arrestin2 recruitment of 80 to 100 relative to DAMGO. SR-17018 also showed strong bias for G protein activation over β-arrestin2 recruitment using mouse proteins, albeit with reduced efficacy for GTPγS binding (Emax = 37%). β-Arrestin2 activation may contribute to opioid tolerance, though it is not the only mechanism of tolerance to these drugs. SR-17018 shows a strikingly different MOR phosphorylation profile from other MOR biased, partial, and full agonists. Additional studies have characterized the interactions of SR-17018 with the MOR, including activational potencies and efficacies at downstream signaling pathways, as well.
The package aimed to raise $739 billion and authorize $370 billion in spending on energy and climate change, $300 billion in deficit reduction, three years of Affordable Care Act subsidies, prescription drug reform to lower prices, and tax reform. According to an analysis by the Rhodium Group, the bill will lower U.S. greenhouse gas emissions between 31 percent and 44 percent below 2005 levels by 2030. On August 7, 2022, the Senate passed the bill (as amended) on a 51–50 vote, with all Democrats voting in favor, all Republicans opposed, and Vice President Kamala Harris breaking the tie. Biden signed the bill on August 16. Before and during the 2021 United Nations Climate Change Conference (COP26), Biden promoted an agreement that the U.S. and the European Union cut methane emissions by a third by 2030 and tried to add dozens of other countries to the effort. Biden pledged to double climate funding to developing countries by 2024. Also at COP26, the U.S. and China reached a deal on greenhouse gas emission reduction. The two countries are responsible for 40 percent of global emissions. In July 2023, when heat waves hit the United States, Biden announced measures to protect the population and said the heat waves were linked to climate change. In April 2024, he unveiled a plan to protect and restore natural water sources (3.2 million hectares of wetlands and 161,000 km of waterways). Biden protected 674 million acres of land and ocean from natural resource exploitation, more than any other president.
Dzhambulat Khatokhov (1999–2020), a Russian boy who weighed 75 lb (34 kg; 5.4 st) at 2 years old and 397 lb (180 kg; 28.4 st) at 13 years old. He was named the world's heaviest child in 2003 by Guinness World Records. Jessica Leonard (born c. 1997–1998), also known as Jessica Gaude, an American girl who reportedly weighed 490 lb (220 kg; 35 st) at 7 years old, and 420 lb (190 kg; 30 st) at 8 years old. Arya Permana (born 2006), an Indonesian boy who weighed 423 lb (192 kg; 30.2 st) at 11 years old. Eugenia Martínez Vallejo, a Spanish girl who lived in the 17th century, gained notoriety for her large size and weight and notably became a court jester for Charles II of Spain. Her obesity is today thought to have been caused by Prader-Willi syndrome.
ALD is caused by mutations in ABCD1, located at Xq28 and demonstrates X-linked recessive inheritance. The gene ABCD1 encodes a peroxisomal membrane transporter which is responsible for transporting very long chain fatty acid substrate into the peroxisomes for degradation. Mutations in this gene that interfere with this process cause this syndrome. Males with an ABCD1 mutation are hemizygous, as they only have a single X chromosome. Female carriers will typically avoid the most severe manifestations of the disease, but often become symptomatic later in life. Although the detection of an ABCD1 mutation identifies an individual who is affected with a form of ALD, there is no genotype–phenotype correlation. Within a family, there will often be several different phenotypes, despite the presence of the same causative mutation. In one case, a family with six affected members displayed five different phenotypes. There are no common mutations that cause ALD, most are private or familial. Almost 600 different mutations have been identified, approximately half are missense mutations, one quarter are frameshifts, with in-frame deletions and splicing defects making up the remainder. The incidence of new mutations in ALD (those occurring spontaneously, rather than being inherited from a carrier parent) is estimated at 4.1%, with the possibility that these are due to germline mosaicism.
Unlike terrestrial silos that maintain value for decades, the imminent expiration of orbital weapons creates a fiscal “use it or lose it" pressure, potentially incentivizing commanders to expend these assets in gray zone conflicts rather than allowing billions of dollars of hardware to burn up in the atmosphere. Ultimately, the deployment of such systems creates a state of "orbital ambiguity" that destabilizes traditional deterrence. Because a Starshield satellite carrying defensive interceptors is indistinguishable on radar from a commercial Starlink satellite or one carrying offensive hypersonic gliders, adversaries are forced to treat the entire constellation as a potential nuclear-equivalent first-strike platform. Strategic theorists such as Forrest Morgan (RAND) and James Acton (Carnegie Endowment) argue that this "warhead ambiguity" creates a “reciprocal fear of surprise attack," incentivizing adversaries to execute massive "blinding" strikes against the constellation or its launch infrastructure at the onset of any crisis, thereby ensuring that a limited conflict immediately escalates to the strategic level.
Sources: en.wikipedia.org
=== δ-scales with two anchoring reference materials === Measuring isotopic ratios by mass spectrometry includes multiple steps in which samples can undergo cross-contamination, including during sample preparation, leakage of gas through instrument valves, the generic category of phenomena called 'memory effects', and the introduction of blanks (foreign analyte measured as part of the sample). As a result of these instrument-specific effects the range in measured δ values can be lower than the true range in the original samples. To correct for such scale compression researchers calculate a "stretching factor" by measuring two isotopic reference materials (Coplen, 1988). For the hydrogen system the two reference materials are commonly VSMOW2 and SLAP2, where δ2HVSMOW2 = 0 and δ2HSLAP2 = -427.5 vs. VSMOW. If the measured difference between the two references is less than 427.5‰, all measured 2H/1H ratios are multiplied by the stretching factor required to bring the difference between the two reference materials in line with expectations. After this scaling, a factor is added to all measured isotopic ratios so that the reference materials attain their defined isotopic values. The carbon system also uses two anchoring reference materials (Coplen et al., 2006a; 2006b).
Other techniques for determining the dosage of CPA have validated this extrapolation, for instance affinity studies and prostatic CPA levels. The affinity of CPA for the AR is around 20-fold lower than that of DHT, and an excess of CPA levels of around 20 to 30 times those of DHT would hence be expected to maximally neutralize androgen signaling. In accordance, different publications have stated based on preclinical experiments that a 2- to 5-fold excess of CPA can inhibit the effects of testosterone by 50%, a 3- to 10-fold excess of CPA can reduce the effects of "potent androgens" (presumably testosterone and/or DHT) by 50%, and a 10-fold excess of CPA can inhibit the effects of testosterone by "almost 100%". High-dose CPA has been found to achieve prostatic levels that are at least 30-fold those of DHT. One study found that levels of CPA in the prostate gland in men being treated with 200 mg/day oral CPA were about 28 times those of DHT. In accordance with the preceding findings, it has been stated that oral doses of CPA of at least 300 mg/day may achieve a combined androgen blockade action in the treatment of prostate cancer. At a dosage of CPA of 100 mg/day in men with prostate cancer, circulating levels of CPA (e.g., 350 ng/mL) are on the order of 200-fold higher than circulating levels of testosterone (e.g., 100 ng/dL). In men who have undergone orchiectomy, 50 mg/day oral CPA results in a 500-fold excess of circulating CPA relative to circulating testosterone.
=== Television === Coatsworth is Nine Network's Medical Expert appearing regularly as a guest on Nine Network programmes. He is presenter of a Nine Network television show he created, Do You Want To Live Forever? which he hosts with Tracey Grimshaw. He has been a guest on multiple television programs including:
=== Novel applications === Due to the versatility of SPR instrumentation, this technique pairs well with other approaches, leading to novel applications in various fields, such as biomedical and environmental studies. When coupled with nanotechnology, SPR biosensors can use nanoparticles as carriers for therapeutic implants. For instance, in the treatment of Alzheimer's disease, nanoparticles can be used to deliver therapeutic molecules in targeted ways. In general, SPR biosensing is demonstrating advantages over other approaches in the biomedical field due to this technique being label-free, lower in costs, applicable in point-of-care settings, and capable of producing faster results for smaller research cohorts. In the study of environmental pollutants, SPR instrumentation can be used as a replacement for former chromatography-based techniques. Current pollution research relies on chromatography to monitor increases in pollution in an ecosystem over time. When SPR instrumentation with a Kretschmann prism configuration was used in the detection of chlorophene, an emerging pollutant, it was demonstrated that SPR has similar precision and accuracy levels as chromatography techniques. Furthermore, SPR sensing surpasses chromatography techniques through its high-speed, straightforward analysis.
Cooking with Canned Milk, including recipes and tips Archived 2017-01-29 at the Wayback Machine PET History – history of evaporated milk and the PET company. Today in Science History – John B. Meyenberg's patent describing his evaporation process of preserving milk
Sources: en.wikipedia.org
=== Population structure === The population of P. aeruginosa can be classified in three main lineages, genetically characterised by the model strains PAO1, PA14, and the more divergent PA7. While P. aeruginosa is generally thought of as an opportunistic pathogen, several widespread clones appear to have become more specialised pathogens, particularly in cystic fibrosis patients, including the Liverpool epidemic strain (LES) which is found mainly in the UK, DK2 in Denmark, and AUST-02 in Australia (also previously known as AES-2 and P2). There is also a clone that is frequently found infecting the reproductive tracts of horses.
{\displaystyle {\boldsymbol {B}}=\lambda ^{2}~\mathbf {n} _{1}\otimes \mathbf {n} _{1}+\lambda ^{2}~\mathbf {n} _{2}\otimes \mathbf {n} _{2}+{\cfrac {1}{\lambda ^{4}}}~\mathbf {n} _{3}\otimes \mathbf {n} _{3}~.}
Portugal's culture has developed due to the influence from various civilisations that have crossed Europe, especially the Mediterranean. Later, during the period of Portugal's engagement in the Age of Discovery, cultural elements from outside of Europe were introduced and became a central element of Portuguese national identity. Portugal is known for its heritage and architecture, sacred sites, festivities, poetry, its music (especially the fado), and cuisine (including its wine). As of 2026, UNESCO inscribed 17 properties in Portugal on the World Heritage List. Portugal's national day is on 10 June, celebrated as the Dia de Portugal, de Camões e das Comunidades Portuguesas (Portugal, Camões, and Portuguese Communities Day).
=== Australia === A person conducting a business or undertaking (PCBU—the new term that includes employers) has duties under the work health and safety (WHS) legislation to ensure a worker affected by alcohol or other drugs does not place themselves or other persons at risk of injury while at work. Workplace policies and prevention programs can help change the norms and culture around substance use. All organisations—large and small—can benefit from an agreed policy on alcohol and drug misuse that applies to all workers. Such a policy should form part of an organisations overall health and safety management system. PCBUs are encouraged to establish a policy and procedure, in consultation with workers, to constructively manage alcohol and other drug related hazards in their workplace. A comprehensive workplace alcohol and other drug policy should apply to everyone in the workplace and include prevention, education, counselling and rehabilitation arrangements. In addition, the roles and responsibilities of managers and supervisors should be clearly outlined. All Australian workplace drug testing must comply with Australian standard AS/NZS4308:2008. In Victoria, roadside saliva tests detect drugs that contain:
Noom is an American privately held digital health company that provides weight management and behavioral health services through a subscription-based mobile application. Founded in 2008, the company combines behavior change psychology with access to weight loss medications and dietary supplements. The platform incorporates elements of cognitive behavioral therapy (CBT) and goal-setting strategies, and its programs are designed to support users in developing healthier habits. In addition to its weight management services, Noom has expanded to offer products related to stress management and general wellness. Noom has received both praise and criticism. Supporters cite its focus on mental and behavioral aspects of health, while critics have raised concerns about the accuracy of its calorie goals, the use of algorithmically determined weight loss targets, and questions about the qualifications of some of its coaching staff.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.